Concepedia

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

Leisl Packer, Sareena Rana, Robert Hayward, Thomas O’Hare, Christopher A. Eide, Ana Paula Rebocho, Sonja J. Heidorn, Matthew S. Zabriskie, Ion Niculescu‐Duvaz, Brian Druker,

Cancer Cell · 2011 · 125 citations · 37 references

DOIFull text

Open access

Concepts

References

37

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

, , +12

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

, , +14

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations

, , +17

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text

, , +14

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag et al. · Nature · 2010 · 1.8K citations · Full text

, , +15